[The effects of clomipramine on diurnal sleepiness and respiratory parameters in a a case of Prader-Willi syndrome].
The association of Prader-Willi-syndrome with breathing disturbances such as sleep apnea syndrome and/or hypoxemia during REM sleep, REM sleep abnormalities and excessive daytime sleepiness is well known. We report the case of an 11-year-old boy who presented with Prader-Willi syndrome, obesity (body mass index [BMI] = 45.6), severe obstructive sleep apnea syndrome and significant daytime sleepiness on multiple sleep latency test. Behavioral disorders did not allowed the use of continuous positive pressure in this patient. Therefore, clomipramine (20 mg per day) was administered. Sleep examination over 8 months showed: slight weight loss (BMI = 44.4), persistence of severe obstructive sleep apnea syndrome, slight improvement in nocturnal hypoxemia, and disappearance of excessive daytime drowsiness with mean sleep latency of 15 min 37 s (less than 2 min before treatment) and no diurnal REM sleep periods. However, clomipramine had no effect on hyperphagia.
Esnault-Lavandier
S
S
Service d'explorations fonctionnelles neurologiques, CHRU, Brest, France.
Mabin
D
D
D002648:Child; D002940:Circadian Rhythm / Q000187:drug effects; D006801:Humans; D006963:Hyperphagia / Q000188:drug therapy / Q000523:psychology; D000860:Hypoxia / Q000188:drug therapy; D008297:Male; D011218:Prader-Willi Syndrome / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D015656:Respiratory Mechanics / Q000187:drug effects*; D012891:Sleep Apnea Syndromes / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology; D012894:Sleep Stages / Q000187:drug effects*; D012895:Sleep, REM / Q000187:drug effects / Q000502:physiology